BioElectronics Announces Publication of Breakthrough Clinical Study for Drug-free Treatment of Chronic Osteoarthritis

FREDERICK, Md., Jan. 5, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced medical devices announced publication of a clinical study demonstrating the efficacy of ActiPatch® Therapy for knee osteoarthritis. This study further validates the positive effects of negating chronic pain central sensitization¹ by ActiPatch® noninvasive neuromodulation therapy. The technology is affordable, effective, and a safe alternative to prescription opioid therapy that is drastically needed in the US and by the 1.5 billion worldwide chronic pain sufferers.  

Oxford University Press on behalf of the British Society of Rheumatology published the study in their journal Rheumatology (www.rheumatology.oxfordjournals.org). The clinical study was an independently conducted, double blind, placebo-controlled, randomized clinical trial. There was a reported statistically significant reduction in pain and a significant improvement in the WOMAC² physical assessments. In addition, patients in the treatment group displayed a reduced use of NSAIDs³ and reported an improvement in their quality of life compared to the placebo group.

"The data from this comprehensive clinical study shows ActiPatch's ability to improve the management of osteoarthritis of the knee," said Ian Rawe, Ph.D., Director of Clinical Research. "We sincerely thank the clinical scientists who conducted this study led by Dr. Gianluca Bagnato, Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Messina, Italy."

This study further demonstrates the noninvasive neuromodulation of ActiPatch® Therapy as the pain pressure threshold increased. This data along with positive treatment of chronic pain reported in our other studies and the recent published registry study, A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag 2015 Vov; 5(6), 413-23 (www.bielcorp.com/clinical-evidence) supports our growing evidence that ActiPatch® Therapy negates central sensitization a core component of chronic pain. The registry study shows successful self-management of chronic pain in arthritis, musculoskeletal, and other chronic pain conditions.  

The published peer reviewed article can be viewed at:
http://rheumatology.oxfordjournals.org/content/early/2015/12/23/rheumatology.kev426.long

1. Central sensitization - a condition wherein the central nervous system mediated pain pathways become hypersensitive
2. WOMAC - Western Ontario and McMaster Universities Osteoarthritis Index
3. NSAIDs – Nonsteroidal anti-inflammatory drugs

About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.

Contact:
Paul Knopick
940.262.3584
[email protected]

SOURCE BioElectronics Corporation

Related Links

http://www.bielcorp.com